share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zaderej Karen L.

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zaderej Karen L.

EyePoint Pharmaceuticals | 4：持股變動聲明-董事 Zaderej Karen L.
美股sec公告 ·  07/12 17:04
Moomoo AI 已提取核心訊息
On July 11, 2024, Karen L. Zaderej, associated with EyePoint Pharmaceuticals, Inc. (EYPT), completed a transaction to acquire 2,000 shares of the company's common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, which is typically related to options or warrants being converted into stock. Following this acquisition, Zaderej's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.
On July 11, 2024, Karen L. Zaderej, associated with EyePoint Pharmaceuticals, Inc. (EYPT), completed a transaction to acquire 2,000 shares of the company's common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, which is typically related to options or warrants being converted into stock. Following this acquisition, Zaderej's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.
2024年7月11日，與eyepoint pharmaceuticals有關的Karen L. Zaderej以零成本完成了一筆交易，以獲取該公司普通股2000股。此項交易被歸類爲衍生證券的行權或轉換，通常是指期權或認股權轉換爲股票。此次收購後，Zaderej在EyePoint Pharmaceuticals的直接持股總數增加到了4000股。
2024年7月11日，與eyepoint pharmaceuticals有關的Karen L. Zaderej以零成本完成了一筆交易，以獲取該公司普通股2000股。此項交易被歸類爲衍生證券的行權或轉換，通常是指期權或認股權轉換爲股票。此次收購後，Zaderej在EyePoint Pharmaceuticals的直接持股總數增加到了4000股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息